Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis.

IF 5.2 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2025-09-26 DOI:10.1007/s11883-025-01346-3

Tannaz Jamialahmadi, Elaheh Mirhadi, Željko Reiner, Kasim Sakran Abass, Wael Almahmeed, Salim S Virani, Amirhossein Sahebkar

{"title":"Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis.","authors":"Tannaz Jamialahmadi, Elaheh Mirhadi, Željko Reiner, Kasim Sakran Abass, Wael Almahmeed, Salim S Virani, Amirhossein Sahebkar","doi":"10.1007/s11883-025-01346-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile.Recent findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"94"},"PeriodicalIF":5.2000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-025-01346-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile.

Recent findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.

查看原文本刊更多论文

吡格列酮对脂蛋白的影响(a): meta分析。

综述的目的：评价吡格列酮对脂蛋白(a)的影响，吡格列酮是噻唑烷二酮家族的一员，以其降糖特性而闻名。吡格列酮被认为可以增强胰岛素敏感性和β细胞功能，并对整体脂质谱有积极影响。近期发现：包括254例患者在内的7项研究（4项随机对照试验和3项非随机对照试验）的荟萃分析显示，吡格列酮治疗后循环Lp(a)水平显著降低（SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007）。在留一敏感性分析中，循环Lp(a)的降低是稳健的。在PubMed， Scopus， Embase和Web of Science中进行了全面的文献检索后获得了所呈现的结果，涵盖了从成立到2025年3月1日的研究。吡格列酮显著降低循环Lp(a)浓度。这种降低可能对高危患者的动脉粥样硬化性心血管疾病（ASCVD）有有益的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.